Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Minimal Residual Disease Clear all
Recruiting No phase listed Observational
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v6, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced May 22, 2026, 4:49 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder, Acute Myeloid Leukemia, Minimal Residual Disease Persistence, Therapy-Related Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced May 22, 2026, 4:49 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Blood and Tissue Collection
Diagnostic Test
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 22, 2026, 4:49 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Blood Draws and Tissue Sample(s)
Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced May 22, 2026, 4:49 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Amyloidosis
Interventions
blood collection, bone marrow collection
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced May 22, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Colorectal Cancer
Interventions
EO2040
Drug
Lead sponsor
Enterome
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced May 22, 2026, 4:49 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced May 22, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Obecabtagene Autoleucel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 22, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Azacitidine (AZC), Venetoclax
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced May 22, 2026, 4:49 AM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome
Interventions
AMG 330
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Duarte, California • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
Interventions
Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Biological · Drug · Radiation + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced May 22, 2026, 4:49 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Colorectal Cancer
Interventions
MRD
Device
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
28
States / cities
Mission Hills, California • Torrance, California • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 22, 2026, 4:49 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
PRGN-3006 T Cells
Drug
Lead sponsor
Precigen, Inc
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Tampa, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced May 22, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Ependymoma
Interventions
Carboplatin
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 21 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced May 22, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia
Interventions
PEG-IFNá-2a
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2015 · Synced May 22, 2026, 4:49 AM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Pediatric AML
Interventions
Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C), Venetoclax, Etoposide, Asparaginase Erwinia Chrysanthemi (recombinant), Intrathecal triple, SOC
Drug · Other
Lead sponsor
Joanna Yi
Other
Eligibility
1 Month to 30 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Leukemia
Interventions
Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced May 22, 2026, 4:49 AM EDT
Approved For Marketing No phase listed Expanded access
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Interventions
gilteritinib
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
32
States / cities
Los Angeles, California • Aurora, Colorado • Pembroke Pines, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced May 22, 2026, 4:49 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Philadelphia Chromosome Positive
Interventions
Blinatumomab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced May 22, 2026, 4:49 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced May 22, 2026, 4:49 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Chronic Myelomonocytic Leukemia in Remission, Graft Versus Host Disease, Hodgkin Lymphoma, Minimal Residual Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Severe Aplastic Anemia, Waldenstrom Macroglobulinemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Sirolimus, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 22, 2026, 4:49 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Cancer, Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer
Interventions
Personalized Cancer Monitoring (PCM)
Diagnostic Test
Lead sponsor
Invitae Corporation
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Indiana • Jacksonville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced May 22, 2026, 4:49 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Myeloma Multiple
Interventions
Belantamab mafodotin, Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced May 22, 2026, 4:49 AM EDT
Suspended Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Interventions
Decoy-resistant interleukin-18, Biospecimen Collection, Bone Marrow Aspiration
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced May 22, 2026, 4:49 AM EDT